Preeclampsia Clinical Trial
Official title:
Treatment Approaches for Preeclampsia in Low-Resource Settings
Preeclampsia is a condition unique to pregnancy characterized by the new onset of
hypertension and proteinuria. Eclampsia, characterized by maternal seizures, is a serious
complication increasing the risk of maternal and infant mortality and morbidity. Magnesium
sulfate is the drug of choice for prevention and treating convulsions in severe preeclampsia
and eclampsia.
Magnesium sulfate is administered parenterally by intramuscular (IM) or intravenous routes
(IV). In general a loading dose of 4 to 5 grams of magnesium sulfate is administered
intravenously followed by an IM injection every 4 hours or by a continuous IV infusion. The
IV regimen achieves more stable serum levels of magnesium but requires the use of an
infusion pump for safe delivery and has a greater potential for inadvertent overdose.
Although magnesium sulfate has been demonstrated as a safe and effective drug for the
treatment and prevention of severe preeclampsia and eclampsia, concerns about the safety of
the drug remain. The IM dosing regimen, while potentially safer, requires repeated painful
IM injections. These limitations in administration hinder the widespread use of magnesium
sulfate despite its demonstrated benefits.
The goal of this research is to develop a system of care that avoids overdose and
facilitates the use of magnesium sulfate for the treatment of preeclampsia. To this end, a
primary objective of this research is to demonstrate the safety of a simple, inexpensive
flow controlled pump system (Springfusor®). This randomized study will compare the
administration of magnesium sulfate by the Springfusor® controlled pump with an IM regimen,
the standard of care in most hospitals in India. The study will document the efficacy and
acceptability of each treatment for patients and staff and compare the cost and time
elements involved in providing each method.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03510286 -
Validation of a PrCr Dipstick Diagnostic Test in Ghana
|
||
Recruiting |
NCT03313024 -
Berlin-Brandenburg Pregnancy Cohort
|
||
Active, not recruiting |
NCT04990141 -
Molecular Screening Method for Preeclampsia (PREMOM)
|
||
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Not yet recruiting |
NCT05999851 -
Multiparametric Assessment of Maternal Vascular Function in the Prediction of Hypertensive Disorders of Pregnancy
|
N/A | |
Recruiting |
NCT02923206 -
Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis
|
N/A | |
Withdrawn |
NCT05016440 -
Lisinopril for Renal Protection in Postpartum Preeclamptic Women
|
N/A | |
Terminated |
NCT02558023 -
The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine
|
Phase 3 | |
Completed |
NCT02854501 -
Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders
|
||
Not yet recruiting |
NCT02541110 -
Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler
|
N/A | |
Completed |
NCT02554604 -
Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies
|
||
Completed |
NCT02384226 -
User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study
|
||
Recruiting |
NCT02337049 -
Preeclampsia Subtypes and Surrogate Markers of CVD Risk
|
N/A | |
Recruiting |
NCT02247297 -
Pancreatic Stone Protein (PSP) in Pregnant Women
|
||
Completed |
NCT02238704 -
Cornell University-Micronutrient Initiative Calcium Supplementation Study
|
N/A | |
Completed |
NCT01195441 -
Prediction and Prevention of Preeclampsia by First Trimester Ultrasound
|
N/A | |
Withdrawn |
NCT01179542 -
The Involvement of Eukaryotic Translation Initiation Factor 4E (eIF4E) in Human Placental Implantation and in the Pathological Pregnancies: Preeclampsia and IUGR
|
N/A | |
Completed |
NCT00456118 -
Study of the Role of Tissular Maternofetal Alloimmunization in Placentation Pathologies
|
||
Recruiting |
NCT00117546 -
Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
|
Phase 4 | |
Completed |
NCT00787241 -
Platelet Count Trends in Pre-eclamptic Parturients
|
N/A |